Management of Crohn’s disease in smokers: Is an alternative approach necessary?

Pilar Nos, Eugeni Domènech

Pilar Nos, Gastroenterology Unit, La Fe University Hospital, 46009 Valencia, Spain
Eugeni Domènech, Digestive Disease Department, Germans Trias i Pujol Hospital, 08916 Badalona, Spain
Pilar Nos, Eugeni Domènech, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain

Author contributions: Nos P and Domènech E contributed equally to this work.

Supported by CIBEREHD, funded by the Instituto de Salud Carlos III, from the Spanish Ministry of Health

Correspondence to: Pilar Nos, MD, PhD, Gastroenterology Unit, La Fe University Hospital, Avda, Campanar, 21, 46009 Valencia, Spain. nos_pil@gva.es
Telephone: +34-96-3622700 Fax: +34-96-1973065
Received: August 2, 2010 Revised: September 1, 2010 Accepted: September 8, 2010 Published online: August 21, 2011

Abstract
Inflammatory bowel disease (IBD) is a chronic condition with a pathogenic background that involves both genetic and environmental factors. Although important progress has been made regarding the former in the last decade, scarce knowledge is available for the latter. In this sense, smoking remains the most important environmental factor in IBD. Active smoking increases the risk of developing Crohn’s disease (CD). Moreover, CD patients who start or continue smoking after disease diagnosis are at risk for poorer outcomes such as higher therapeutic requirements and disease-related complications, as compared to those patients who quit smoking or who never smoked. However, the harmful effect of active smoking is not uniform in all patients or in all clinical scenarios. Interventions designed to facilitate smoking cessation may impact the course of the disease. In this article, the available evidence of the deleterious effects of smoking on CD is reviewed in detail, and alternative therapeutic approaches to CD in smokers are proposed.

© 2011 Baishideng. All rights reserved.

Key words: Tobacco; Crohn’s disease; Therapy; Smoking cessation; Recurrence; Complications

Peer reviewer: Stephen M Kavic, MD, FACS, Assistant Professor of Surgery, Department of Surgery, University of Maryland School of Medicine, 22 South Greene Street, Room S4B09, Baltimore, MD 21201, United States

Nos P, Domènech E. Management of Crohn’s disease in smokers: Is an alternative approach necessary? World J Gastroenterol 2011; 17(31): 3567-3574 Available from: URL: http://www.wjgnet.com/1007-9327/full/v17/i31/3567.htm DOI: http://dx.doi.org/10.3748/wjg.v17.i31.3567

INTRODUCTION
Crohn’s disease (CD) is a chronic idiopathic inflammatory bowel disease of unknown etiology. The pathogenesis of CD is multifactorial, and several factors have been implicated in its development including genetic and environmental ones[1]. Differences in incidence rates across age, time, and geographic areas suggest that environmental factors are implicated in inflammatory bowel disease (IBD), but only cigarette smoking and appendectomy have consistently been identified as risk factors, the former being the one with the greatest impact on both CD development and disease behavior. The disease is more frequent in active smokers than in non-smokers[2,3], and smoking may alter the natural course of CD since smokers are more likely to develop complications and relapses, and to need surgery[4,5].

There is evidence that interventions designed to facilitate smoking cessation may improve the course of the disease[6]. This article reviews the available data on smoking and its effects among patients with an established diagnosis of CD.
CLINICAL COURSE AND PROGNOSIS OF CD IN SMOKERS

It is well known that CD is more common in smokers[8]. The relationship between smoking and worsening of the clinical course of the disease has also been established, though the underlying mechanisms are complex and are still subject to research. Of note is the fact that in the case of ulcerative colitis (UC), the effects of smoking are the opposite of those seen in CD. The potential mechanisms explaining such opposing behavior include the different effects of smoking upon cellular and humoral immune function in both diseases, their cytokine profiles, and bowel wall motility and permeability.[6]

Among the elements contained in tobacco smoke, it seems clear that nicotine has the greatest impact upon the clinical course of CD[7]. However, it has recently been established that tobacco glycoprotein may be responsible for promoting a Th1 cell response[8], while nicotine maintains its relevance as the cause of anti-inflammatory action in UC[9]. Smokers show an increased production of reactive oxygen species and a lessened antioxidant capacity[10]; this, in turn, could act synergically with oxidative stress in CD[11]. Moreover, environmental factors may interact with genetic factors. In this sense, recent research has demonstrated that smoking may influence the gene expression profile of the colonic mucosa in CD patients[12].

Smoking has been associated with a poorer prognosis of CD and a worse quality of life[13]. Holdstock et al[8] reported for the first time that CD patients who were active smokers had an increased number of disease relapses and more severe pain; this was also associated with an increased probability of hospital admission and intestinal resection among patients with ileal involvement. This increased relapse rate was later estimated to be two-fold higher among smokers in a Canadian prospective study involving 152 CD patients[14].

Some epidemiological factors such as gender or disease location may influence the impact of smoking habits on CD outcomes. Most data on the impact of smoking on CD natural history come from the studies performed in the Hôpital Saint Antoine in Paris[16-18]. One of their first studies included 400 consecutive CD patients who were specifically interviewed to assess the effects of smoking upon the long-term course of the disease[16]. The need for corticosteroids and immunomodulators was greater among smokers, but no differences were found in terms of intestinal resection requirements except in those patients who started smoking after CD diagnosis. In addition, the deleterious effect of smoking was found to be dose-dependent, and more marked among women. In a later study, the same authors underscored the existence of a poorer prognosis among women[18].

Exclusive colon involvement possibly does not imply a poorer disease course in smokers as compared to non-smokers. In another study published by the same French group that involved 622 CD patients, the risk of relapse was found to be significantly greater among patients with inactive disease and without colon involvement[19]. A multicenter survey involving 457 CD patients from 19 European countries evaluated several clinical parameters at the time of disease diagnosis. Prescription of corticosteroids or immunomodulators - as a surrogate marker of a less favorable disease course - proved greater among smokers within the first year from disease diagnosis[20]. The proportion of individuals with ileal involvement was likewise significantly greater among smokers, in agreement with the findings in our own setting[21]. In fact, these higher surgical requirements among smokers could be related to a more frequent ileal involvement[22].

The negative effects of smoking seem to be dose-dependent, with the risk of a poor disease progression being particularly high among heavy smokers. Lindberg et al[23], in a series of 231 CD patients, reported that heavy smokers (over 10 cigarettes/d) presented an increased risk of surgery at 5 and 10 years from diagnosis as compared to patients who never smoked (OR 1.14 and 1.24, respectively). The risk for further operations was even higher, with an OR at 10 years of 1.79. In another study, the proportion of time with intestinal inflammatory activity during follow-up was reported to be 37% among non-smokers, 46% among patients who smoked less than 10 cigarettes/d, and 48% among heavy smokers[24]. Surprisingly, a recent study has reported no unfavorable clinical course in smokers, though passive smokers did show a poorer course[25].

Smoking has been correlated to a lesser prevalence of inflammatory (non-stricturing, non-penetrating) behavior of the disease, thus suggesting that tobacco consumption influences progression towards fistulizing or stricturing disease[22,26,27]. Available data are contradictory when assessing the risk of perianal disease, since it was included in the definition of the fistulizing CD pattern in the initial Vienna phenotypic classification of CD[28], but not in the Montreal adaptation[29]. Of note is the fact that phenotypic characteristics may differ greatly according to the ethnic origin of the studied population. Thus, for the French Canadian population, the phenotypic pattern has been differentiated from that of other Caucasian populations, with an important trend towards aggressive fistulizing behavior[30]. In this population, the association between smoking and CD is strong enough to have possible implications. The lack of association between smoking and CD has now been established in Jewish patients in Israel. The stronger genetic tendency in CD may contribute to this discrepancy[31].

POST-SURGICAL RECURRENCE IN SMOKERS

Intestinal resection still remains a cornerstone in the management of CD despite the availability of biologic agents and the widespread use of immunomodulators. Recently, two independent studies reported a cumulative probability of undergoing abdominal surgery of about 40% and 60% within five and ten years from disease diagnosis, respectively, in an adult hospital-based and in a pediatric population-based cohort of CD patients[30,31]. However, disease recurrence is almost the rule after a “curative” resection and, for this reason, preventive algorithms have been repeatedly
SMOKING INFLUENCING THERAPEUTIC RESPONSE

Although it has been proven that smoking increases thera-
smoking and the response to thiopurines. The study included 163 IBD patients (103 CD and 60 UC) who started thiopurine therapy because of steroid dependency and who were followed up in two Catalan centers. Smoking habits at the time thiopurines were started were carefully assessed. No difference in the proportion of responders was found, in CD or in UC, suggesting that, once again, tobacco does not influence the efficacy of drug therapies in IBD. Results remained the same when several exploratory sub-analyses combining gender, disease location (colonic or ileal involvement), colonic or ileal isolated disease) and smoking habits (non-smokers, smokers, heavy smokers of > 10 cigarettes/d) were performed. Of note, CD responders who continued smoking had a higher rate of relapses during follow-up, although this did not lead to higher requirements of biological agents or surgery. Surprisingly, the authors found that treatment discontinuation because of thiopurine-related side effects was independently associated with active smoking in the multivariate analysis. This led to a reduced treatment efficacy among CD patients (as compared to UC) when evaluated by intention-to-treat analysis. Similarly, the largest survey of thiopurine-related toxicity in IBD patients reported to date, which included 3900 IBD patients treated with thiopurines from the Spanish ENEIDA Register [a nationwide register of IBD patients promoted by the Spanish Working Group in IBD (GETECCU)] found that both hepatotoxicity and acute pancreatitis were significantly more frequent in CD as compared to UC, although the smoking status information when starting thiopurines was not available.

In summary, it seems clear that active smoking increases the risk of a more disabling course of CD, particularly in patients with ileal disease, women, and heavy smokers. This harmful effect might be genetically modulated, as seen in certain ethnic groups. Once those populations at risk are identified, interventional measures to ensure smoking cessation should be considered (Figure 2). If the patient fails in giving up smoking, more intensive CD treatment strategies such as earlier use of immunomodulators and/or biological agents should be taken into account in order to anticipate complications.

**INTERVENTIONS FOR SMOKING CESSATION: ARE THEY EFFECTIVE?**

The strongest evidence of the deleterious effect of tobacco consumption upon the course of CD is precisely the beneficial consequences of smoking cessation. In the cohort study published by Cosnes et al., patients were followed up for 12-18 mo and a lower relapse risk was observed among those patients who stopped smoking for at least 6 mo. In ex-smokers, the clinical course was similar to that seen in patients who have never smoked.

There is no doubt regarding the beneficial effects of smoking cessation upon the clinical course of CD. Such benefit might be even greater than that afforded by the use of thiopurines as maintenance therapy. The only interventional study published to date included 474 consecutive smokers with CD who were offered a smoking cessation program. Patients who stopped smoking for more than one year (quitters) were included in a prospective follow-up study comparing disease course and therapeutic requirements with two control groups - continuing smokers and non-smokers - matched for age, gender, disease location and activity. Fifty-nine patients were able to quit smoking (12%). After a median follow-up of 29 mo, the risk of flare-up in quitters did not differ from that in non-smokers, and was lower than that of smokers (Figure 3). Steroid and immunomodulator requirements were similar among quitters and non-smokers, but greater among smokers. Finally, the risk of surgery was not significantly different between the three groups. Interestingly, the authors found that the physician in charge, previous intestinal surgery, high socioeconomic status and, in women, oral contraceptive use, were predictors of quitting tobacco consumption.

Despite the negative effect of smoking on health, and specifically on the clinical course of CD, smoking cessation is not an easy matter. Management of smokers is based on two complementary interventions: behavioral intervention and drug therapy. Physicians must remember the “four As” needed to correctly address this topic: (1) asking about current smoking habit; (2) advising them to stop; (3) assisting the patient by way of the available methods; and (4) arranging follow-up. It is very important to stress the importance of smoking cessation, since patients who are aware of the strongly negative impact of the habit upon the course of the disease will find it easier to stop smoking. Unfortunately, CD patients are too often unaware of the risks that smoking poses for their disease, thus indicating the need for increased patient information with regard to the effects of smoking on CD.

Recently, an interesting study designed to increase the motivation to stop smoking involved 140 smokers without CD. Individuals were informed about the characteristics of CD, and underwent a genetic study (NOD2/CARD15 mutations) in order to classify them according to the risk of developing the disease. The results confirmed the hypothesis that increased information on the genetic burden of CD could modify the intention to quit smoking, to the extent that those individuals at higher risk showed a greater willingness to stop smoking.

---

**Figure 2** Algorithm for patient in medically or surgically induced remission. Low risk is defined as long-standing, short segment fibrostenotic disease without or with minimal active inflammation. TNF: Tumor necrosis factor.
Behavioral interventions designed to stop smoking

Behavioral interventions designed to facilitate smoking cessation include specific warnings from the general practitioner, intensive advice or counseling by specialists on disease-related risks, and supportive measures in the form of written material or telephone calls.

Simple warning by physicians to stop smoking has shown some usefulness in the studies conducted by the Cochrane Tobacco Addiction Review Group[56], though the effect is relatively poor[57]; assuming an unassisted quitting rate of 2%-3%, a brief advice intervention can increase quitting by a further 1%-3%. Direct comparison of intensive vs minimal advice has shown a small advantage for intensive advice [relative risk (RR) 1.37, 95% confidence interval (95% CI): 1.20-1.56]. Additional components appear to exert only a minor effect, though a small additional benefit is derived from more intensive interventions compared to very brief interventions.

Behavioral interventions are useful, especially when combined with drug therapy, and particularly over the short term. Motivational interviewing is a directive patient-centered style of counseling designed to help people to explore and resolve ambivalence about behavior change. It was developed as a treatment for alcohol abuse, but may help smokers to make a successful attempt to quit smoking[58]. Innovative effective smoking cessation interventions are required to appeal to those who are not accessing traditional cessation services. Mobile phones are widely used and are now well integrated into daily life, particularly among young adults - as most CD patients are at disease onset. Mobile phones are a potential medium for the delivery of health programs such as those designed to facilitate smoking cessation, but current evidence shows no effect of mobile phone-based smoking cessation interventions upon long-term outcome[59]. Pooled data from the Internet and mobile phone programs show statistically significant increases in both short- and long-term self-reported quitting (RR 2.03, 95% CI: 1.40-2.94). While short-term results are positive, more rigorous studies of the long-term effects of mobile phone-based smoking cessation interventions are needed.

Many European centers have outpatient clinics specifically targeted to help smoking cessation by means of a multidisciplinary approach (with nurses, psychologists, pneumologists and general practitioners), but drug therapy is almost universally used in these clinics as a complement to behavioral interventions.

Drug therapy

Pharmacological smoking cessation aids are recommended for all smokers who are trying to quit, unless contraindicated. The available drugs include the following.

Nicotine replacement products: Such products offer a way to administer nicotine without smoking. They can be used in the form of patches, chewing gum, or nasal spray formulations. The aim of nicotine replacement therapy (NRT) is to temporarily replace much of the nicotine from cigarettes to reduce motivation to smoke and nicotine withdrawal symptoms, thereby easing the transition from cigarette smoking to complete abstinence. A recent Cochrane review[60] identified 132 trials on the use of NRT in people willing to quit smoking. Of these, 111 trials involving over 40,000 participants contributed to the primary comparison between any type of NRT and a placebo or non-NRT control group. The RR of abstinence for any form of NRT relative to control was 1.58 (95% CI: 1.50-1.66). The pooled RR for each type were 1.43 (95% CI: 1.33-1.53, 53 trials) for nicotine gum, 1.66 (95% CI: 1.53-1.81, 41 trials) for nicotine patch, 1.90 (95% CI: 1.36-2.67, 4 trials) for nicotine inhaler, 2 (95% CI: 1.63-2.45, 6 trials) for oral tablets/lozenges, and 2.02 (95% CI: 1.49-3.73, 4 trials) for nicotine nasal spray. The effects were largely independent of the duration of therapy, the intensity of the provided additional support, or the setting in which NRT was offered. The effect was similar in a small group of studies that aimed to assess the use of NRT obtained without a prescription. In highly dependent smokers there was a significant benefit of 4 mg gum compared to 2 mg gum, but weaker evidence of a benefit from higher doses in patch form. There was evidence that combining a nicotine patch with a rapid delivery form of NRT is more effective than a single type of NRT. Only one study directly compared NRT to another drug treat-
management. In this study the smoking cessation rates with nicotine patch were lower than with the antidepressant bupropion.

**Bupropion:** While not a substitute for nicotine, this drug reduces the anxiety associated with not smoking. Bupropion is an atypical antidepressant that acts as a norepinephrine and dopamine reuptake inhibitor. Initially researched and marketed as an antidepressant, bupropion was subsequently found to be effective as a smoking cessation aid. Conversely to selective serotonin reuptake inhibitors (e.g. fluoxetine), the antidepressants bupropion and nortriptyline contribute to long-term smoking cessation. It has been suggested that the mode of action of bupropion and nortriptyline could be independent of their antidepressant effect, and that their efficacy is similar to that of nicotine replacement.

**Varenicline:** This new smoking dishabitation agent acts by blocking the nicotinic receptors and induces similar effects to that of nicotine, counteracting the craving to smoke, lessening the withdrawal syndromes, and reducing the gratifying and reinforcing effects of smoking. Varenicline was developed as a nicotine receptor partial agonist from cytisine, a widely used drug in Central and Eastern Europe for smoking cessation. Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). The first reports of trials with varenicline were published in 2006. This drug offers higher efficacy rates (smoking cessation) than those of the existing alternatives. Varenicline increased by 2- and 3-fold the chances of successful long-term smoking cessation as compared with pharmacologically unassisted quitting attempts. There is a need for independent community-based trials of varenicline to test its efficacy and safety in smokers with varying co-morbidities and risk patterns. Likewise, there is a need for further trials of the efficacy of treatment extended beyond 12 wk.

In February 2008, the United States Food and Drug Administration issued a public health advisory note, reporting a possible association between varenicline and an increased risk of behavior change, agitation, depressed mood, and suicidal ideation and behavior. The possible risks of serious adverse events occurring while using varenicline or bupropion should always be weighed against the significant health benefits of quitting smoking that include not only a better prognosis for CD but also a reduction in the chance of developing lung or heart disease, and cancer.

**MANAGEMENT OF SMOKING RELAPSE**

Less than 10% of all patients who quit smoking without medical help are able to maintain abstinence over the long term. Interventions, whether pharmacological or surgical, increase the long-term cessation rates as compared to control interventions, though there is a permanent reduction in the general success rates due to the fact that a proportion of individuals who are initially able to stop smoking subsequently relapse over time.

At present there is insufficient evidence to support the use of any specific behavioral intervention for helping smokers who have successfully quit for a short time to avoid relapse. The verdict is strongest for interventions focusing on identifying and resolving tempting situations, as most studies have been concerned with these. There is little research available regarding other behavioral approaches. Extended treatment with varenicline may prevent relapse, though extended treatment with bupropion is unlikely to have a clinically important effect. Studies of extended treatment with nicotine replacement are needed.

**DIFFERENT APPROACH TO CD PATIENTS WHO CONTINUE SMOKING**

When compared to similar data for the general population, patients with CD are not found to be more refractory to smoking cessation. CD patients must be informed of the importance of smoking cessation for the course of their disease, and individualized medical intervention should be established to reach this objective. This is particularly important in smoking women with CD. Nicotine patch replacement therapy during the first 6-12 wk of abstinence is appropriate in heavy smokers and in smokers with a high degree of tobacco dependency. If, despite reinforced medical advice, the patient is unable to quit smoking, referral to a specific smoking cessation clinic is recommendable. If this is not possible, then the physician should offer behavioral and drug treatment support.

Varenicline is likely to be clinically and cost-effective for smoking cessation, assuming that each user makes a single attempt to quit smoking. The key area of uncertainty concerns the long-term experience of subjects who have remained abstinent beyond 12 mo. Guidelines issued by the National Institute for Health and Clinical Excellence in July 2007 state that varenicline is recommended under its licensed indications as an option for smokers who have expressed their wish to quit smoking, and that varenicline should normally be prescribed only as part of a behavioral support program. In the presence of depressive symptoms or other contraindications to the use of these drugs, NRT may be used.

Regardless of whether a CD patient is not able to stop smoking, a close monitoring (clinical and/or endoscopic) is recommended and early introduction of more intensive therapeutic strategies (immunomodulators and/or biological agents) should be considered, especially in women with ileal involvement.

**REFERENCES**

1. Lakatos PL, Fischer S, Lakatos L, Gal I, Papp J. Current concept on the pathogenesis of inflammatory bowel disease: crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal
integrity take “toll”? World J Gastroenterol 2006; 12: 1829-1841
2 Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989; 34: 1841-1854
3 Mahid SS, Minor KS, Soto RE, Hormung CA, Gelandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc 2006; 81: 1462-1471
4 Karban A, Eliakim R. Effect of smoking on inflammatory bowel disease: Is it disease or organ specific? World J Gastroenterol 2007; 13: 2150-2152
5 Johnson GJ, Cosnes J, Mansfield JC. Review article: smoking cessation as primary therapy to modify the course of Crohn’s disease. Aliment Pharmacol Ther 2005; 21: 921-931
6 Birrenbach T, Böcker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. World J Gastroenterol 2003; 9: 364-368
7 Galeazzi F, Blemnerhassett PA, Qiu B, O’Byrne PM, Collins SM. Cigarette smoke aggravates experimental colitis in rats. Gastroenterology 1999; 117: 877-883
8 Francus T, Romano PM, Manzo G, Fonacier L, Arango N, Szabo P, IL-1, IL-6, and PDGF mRNA expression in alveolar cells following stimulation with a tobacco-derived antigen. Cell Immunol 1992; 145: 156-174
9 McGillov WW, Wallace JM, Heavey PM, Ridley DL, Rowland R. Hypothesis about mechanisms through which nicotine might exert its effect on the interdependence of inflammation and gut barrier function in ulcerative colitis. Inflamm Bowel Dis 2007; 13: 108-115
10 Kalra J, Chaudhary AK, Frasad K. Increased production of oxygen free radicals in cigarette smokers. Int J Exp Pathol 1991; 72: 1-7
11 Beltrán B, Nos P, Dasi F, Iborra M, Bastida G, Martínez M, O’Connor JE, Sáez G, Moret I, Ponce J. Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naïve and treated Crohn’s disease. PLoS One 2009; 4: e6210
12 Cosnes J. Smoking, physical activity, nutrition and lifestyle: environmental factors and their impact on IBD. Dig Dis 2010; 28: 411-417
13 Holdstock G, Savage D, Harman M, Wright R. Should patients with inflammatory bowel disease smoke? Br Med J (Clin Res Ed) 1984; 288: 362
14 Timmer A, Sutherland LR, Martin F. Oral contraceptive use and smoking are risk factors for relapse in Crohn’s disease. The Canadian Mesalazine for Remission of Crohn’s Disease Study Group. Gastroenterology 1998; 114: 1143-1150
15 Cosnes J, Carbonnel F, Beaugerie L, Le Quintré Y, Gendre JP. Effects of cigarette smoking on the long-term course of Crohn’s disease. Gastroenterology 2004; 126: 45-52
16 Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Cattan S, Gendre J. Effects of current and former cigarette smoking on the clinical course of Crohn’s disease. Aliment Pharmacol Ther 1999; 13: 1403-1411
17 Cosnes J, Beaugerie L, Carbonnel F, Gendre JP. Smoking cessation and the course of Crohn’s disease: an intervention study. Gastroenterology 2001; 120: 1093-1099
18 Russell MG, Volovicés A, Schoon EJ, van Wijlck EG, Logan RF, Shivananda S, Stockbrügger RW. Inflammatory bowel disease: is there any relation between smoking status and disease presentation? European Collaborative IBD Study Group. Inflamm Bowel Dis 1998; 4: 182-186
19 Bustamante M, Nos P, Hoyos M, Hinojosa J, Molés JR, Garcia-Herola A, Berenguer J. Relationship between smoking and colonic involvement in inflammatory bowel disease. Rev Esp Enferm Dig 1998; 90: 833-840
20 Aldhous MC, Drummond HE, Anderson N, Smith LA, Arnott ID, Satsangi J. Does cigarette smoking influence the phenotype of Crohn’s disease? Analysis using the Montreal classification. Am J Gastroenterol 2007; 102: 577-588
21 Lindberg E, Järnerot G, Huitfeldt B. Smoking in Crohn’s disease: effect on localisation and clinical course. Gut 1992; 33: 779-782
22 Sekspi P, Nion-Larmurier I, Sokol H, Beaugerie L, Cosnes J. Effects of light smoking consumption on the clinical course of Crohn’s disease. Inflamm Bowel Dis 2009; 15: 734-741
23 van der Heide F, Dijkstra A, Weersma RK, Albersnagel FA, van der Logt EM, Faber KN, Sluiter WJ, Kleibeuker JH, Djikstra G. Effects of active and passive smoking on disease course of Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis 2009; 15: 1199-1207
24 Picco MF, Bayless TM. Tobacco consumption and disease duration are associated with fustilizing and stricking behaviors in the first 8 years of Crohn’s disease. Am J Gastroenterol 2003; 98: 1363-1368
25 Louis E, Michel V, Hugot JP, Reenaers C, Fontaine F, Delforge M, El Yafi F, Colombel JF, Belaiche J. Early development of stricking or penetrating pattern in Crohn’s disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 2003; 52: 552-557
26 Lakatos PL, Czegledi Z, Szamosi T, Banai J, David G, Zsigmond F, Pandur T, Erdelyi Z, Gemela O, Papp J, Lakatos L. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn’s disease. World J Gastroenterol 2009; 15: 3504-3510
27 Gasche C, Schonmerich J, Brynskov J, D’Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR. A simple classification of Crohn’s disease: report of the Working Party for the World Congress of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6: 8-15
28 Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus Jr EY, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhardt AH, Targan SR, Vermeire S, Warren BF. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology, Can J Gastroenterol 2005; 19 Suppl A: 5-36
29 Bhar M, Nguyen GC, Pare P, Lahaye R, Deslandes C, Bernard EJ, Aumais G, Jobin G, Wild G, Cohen A, Langelier D, Brant SR, Dassopoulos T, McGovern D, Torres E, Duerr R, Regueiro M, Silverberg MS, Steinhardt H, Griffiths AM, Elkadri A, Cho J, Proctor D, Goyette P, Rios J, Buttor P. Phenotypic and genotypic characteristics of inflammatory bowel disease: a comparison of IBD in French Canadians: comparison with a large North American repository. Am J Gastroenterol 2009; 104: 2233-2240
30 Ben-Horin S, Avidan B, Yanai H, Lang A, Chowers Y, Bar-Meir S. Familial clustering of Crohn’s disease in Israel: prevalence and association with disease severity. Inflamm Bowel Dis 2005; 11: 1317-1358
31 Veloso FT, Ferreira JT, Barros L, Almeida S. Clinical outcome of Crohn’s disease: analysis according to the vienna classification and clinical activity. Inflamm Bowel Dis 2001; 7: 306-313
32 Romberg-Camps MJ, Dagnelie PC, Kester AD, Hesselink van de Kruijf MA, Cilissen M, Engels LG, Van Deursen C, Hameeteman WH, Wolters FL, Russel MG, Stockbrügge RW. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol 2009; 104: 371-383
33 Lemann M. Review article: can post-operative recurrence in Crohn’s disease be prevented? Aliment Pharmacol Ther 2006; 24 Suppl 3: 22-28
34 Regueiro M. Management and prevention of postoperative Crohn’s disease. Inflamm Bowel Dis 2009; 15: 1583-1590
35 Yamamoto T. Factors affecting recurrence after surgery for Crohn’s disease. World J Gastroenterol 2005; 11: 3971-3979
36 Renda MC, Orlando A, Civitacevchia G, Criscuoli V, Maggio A, Moccia F, Rossi F, Scimeca D, Modesto I, Oliva L, Cottone M. The role of CARD15 mutations and smoking in the course of Crohn’s disease in a Mediterranean area. Am J Gastroenterol 2007; 102: 577-588
Nos P et al. Managing CD in smokers

Gastroenterol 2008; 103: 649-655

38 Papay P, Reinsch W, Ho E, Gratzer C, Lissner D, Herkner H, Riss S, Dejaco C, Miehsler W, Vogelsang H, Novacke G. The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery. Am J Gastroenterol 2010; 105: 1158-1164

39 Sutherland LR, Ramcharan S, Bryant H, Fick G. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 1990; 98: 1123-1128

40 Cosnes J, Nion-Larmurier I, Afchain P, Beaugerie L, Gendre JP. Gender differences in the response of colitis to smoking. Clin Gastroenterol Hepatol 2004; 2: 41-48

41 Reif S, Lavry A, Keter D, Fich A, Eliakim R, Halak A, Broide E, Niv Y, Ron Y, Patz J, Odes S, Villa Y, Gilat T. Lack of association between smoking and Crohn's disease but the usual association with ulcerative colitis in Jewish patients in Israel: a multicenter study. Am J Gastroenterol 2000; 95: 474-478

42 Jang JY, Kim HJ, Jung JH, Chae MJ, Kim NH, Lee SK, Joo KR, Dong SH, Kim BH, Chang YW, Lee JL, Chang R. [The role of smoking as a risk factor in inflammatory bowel diseases: single center study in Korea]. Korean J Gastroenterol 2006; 47: 198-204

43 Aget F, Cosnes J, Hassani Z, Gornet JM, Gendre JP, Lémann M, Beaugerie L. Impact of pregnancy on the clinical activity of Crohn's disease. Aliment Pharmacol Ther 2005; 21: 509-513

44 Cottone M, Rosselli M, Orlando A, Oliva L, Puleo A, Cappello M, Traina M, Tonelli F, Pagliaro L. Smoking habits and recurrence in Crohn's disease. Gastroenterology 1994; 106: 643-648

45 Cortés X, Zabana Y, Paredes JM, Mañosas M, Boix J, Moreno-Osset E, Cabré E, Domènech E. Azathioprine and smoking habits are the only predictors of severe endoscopic postoperative recurrence in Crohn's disease: results of a prospective study. J Crohn Colitis 2010; 1: 564 (abstract)

46 Parsi MA, Achkar JP, Richardson S, Katz J, Hammel JP, Lashner BA, Brzezinski A. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002; 123: 707-713

47 Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003; 17: 1451-1457

48 Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescaute P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002; 97: 2357-2363

49 Fefferman DS, Lohvadia PJ, Alshahi M, Falchuk K, Peppercorn MA, Shah SA, Farrell RJ. Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease. Inflamm Bowel Dis 2004; 10: 346-351

50 Orlandi A, Colombo E, Kohn A, Biancone L, Rizzello F, Viscido A, Sostegni R, Benazzato L, Castiglione F, Papic A, Meucci G, Riegler G, Moccia F, Cassinotti A, Cosintino R, Geremia A, Morselli C, Angelucci E, Lavagna A, Rispo A, Bossa F, Scimera D, Cottone M. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis 2005; 37: 577-583

51 Mañosas M, García-Planella E, Carnín S, Gordillo J, Cabré E, Poca M, Guerrier C, Doménech E. Influence of smoking on azathioprine efficacy in steroid-dependent inflammatory bowel disease. Gut 2005; 58 (Suppl II): A323 (abstract)

52 Chaparro M, Ordás i, Cabré E, García V, Bastida G, Peñalva M, Gomollón F, García-Planella E, Merino O, Gutiérrez A, Esteve M, Andreu M, Vázquez N, Hinojosa J, Vera L, Muñoz F, Mendoza JL, Cabriada JL, Montoro M, Barreiro M, Ceha G, Saro C, Aldeguer X, Barrio J, Mate J, Jisbert JP. Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3,900 patients. J Crohn Colitis 2010; 4: S85 (abstract)

53 Ryan WR, Ley C, Allan RN, Keighley MR. Patients with Crohn's disease are unaware of the risks that smoking has on their disease. J Gastrointest Surg 2003; 7: 706-711

54 Shields PL, Low-Beer TS. Patients' awareness of adverse relation between Crohn's disease and their smoking: questionnaire survey. BMJ 1996; 313: 265-266

55 Wright AJ, Takeichi C, Whitwell SC, Hankins M, Marteau TM. The impact of genetic testing for Crohn's disease, risk magnitude and graphical format on motivation to stop smoking: an experimental analogue study. Clin Genet 2008; 73: 306-314

56 Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev 2004; CD000165

57 Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev 2008; CD000165

58 Dai DT, Cahill K, Qin Y, Tang JL. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev 2010; CD000693

59 Whittaker R, Borland R, Bullen C, Lin BB, McRobbie H, Rodgers A. Mobile phone-based interventions for smoking cessation. Cochrane Database Syst Rev 2009; CD006611

60 Stead LF, Peraera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008; CD000146

61 Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; CD000531

62 Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo and sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2010; 296: 56-63

63 Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2008; CD006103

64 Cahill K, Stead L, Lancaster T. A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Saf 2009; 32: 119-135

65 A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA 2000; 283: 3244-3254

66 Hajek P, Stead LF, West R, Jarvis M, Lancaster T. Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev 2009; CD003599

67 Hilsden RJ, Hodgins D, Czechowsky D, Verhoef MJ, Sutherland LR. Attitudes toward smoking and smoking behaviors of patients with Crohn's disease. Am J Gastroenterol 2001; 96: 1849-1853

68 Doggrell SA. Which is the best primary medication for long-term smoking cessation—nicotine replacement therapy, bupropion or varenicline? Expert Opin Pharmacother 2007; 8: 2903-2915

69 Hind D, Tappenden P, Peters J, Kenjegalieva K. Varenicline in the management of smoking cessation: a single technology appraisal. Health Technol Assess 2009; 13 Suppl 2: 9-13

S- Editor Sun H L- Editor Logan S E- Editor Ma WH